

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DO. T NO.  
231/198SERIAL NO.  
~~To Be Assigned~~APPLICANT:  
Ben Margolis et al.FILING DATE:  
Herewith 1/23/98

GROUP: 1642

JCS 1 U.S. PTO  
09/012369  
01/23/98

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	NAME	CLASS	SUB CLASS	FILING DATE
1/2	AA	4	3	7	6	1	1	0		03/08/83	David et al.			
1/2	AB	4	1	9	5	1	2	8		03/25/80	Hildebrand et al.			
1/2	AC	4	2	4	7	6	4	2		01/27/81	Hirohara et al.			
1/2	AD	4	2	2	9	5	3	7		10/21/80	Hodgins et al.			
1/2	AE	3	9	6	9	2	8	7		07/13/76	Jaworek et al.			
1/2	AF	4	9	4	6	7	7	8		08/07/90	Ladner et al.			
1/2	AG	3	6	9	1	0	1	6		09/12/72	Patel			

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER								DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
														YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1/2	AH	Aaronson, "Growth Factors and Cancer", <u>Science</u> 254:1146-1153 (1991)
1/2	AI	Adelman et al., "In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone", <u>DNA</u> 2:183-193 (1983)
1/2	AJ	Barbacid et al., "The <i>trk</i> family of tyrosine protein kinase receptors", <u>Biochimica et Biophysica Acta</u> 1072:115-127 (1991)
1/2	AK	Bargmann et al., "The <i>neu</i> oncogene encodes an epidermal growth factor receptor-related protein", <u>Nature</u> 319:226-230 (1986)
1/2	AL	Batzer et al., "The Phosphotyrosine Interaction Domain of Shc Binds an LXNPXY Motif on the Epidermal Growth Factor Receptor," <u>Molecular and Cellular Biology</u> 15:4403-4409 (1995)
1/2	AM	Bird et al., "Single-Chain Antigen-Binding Proteins", <u>Science</u> 242:423-426 (1988)
1/2	AN	Blaikie et al., "A Region in Shc Distinct from the SH2 Domain Can Bind Tyrosine-phosphorylated Growth Factor Receptors," <u>J. Biol. Chem.</u> 269:32031-32034 (1994)
1/2	AO	Bongarzone et al., "High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma", <u>Oncogene</u> 4:1457-1462 (1989)
1/2	AP	Campbell et al., "Polioyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen," <u>Proc. Natl. Acad. Sci. USA</u> 91:6344-6348 (1994)
1/2	AQ	Colbère-Garapin et al., "A New Dominant Hybrid Selective Marker for Higher Eukaryotic Cells", <u>J. Mol. Biol.</u> 150:1-14 (1981)
1/2	AR	Cole et al., "The EBV-Hybridoma Technique and its Application to Human Lung Cancer", pp. 77-96 in <u>Monoclonal Antibodies and Cancer Therapy</u> , eds. Reisfeld and Sell, Alan R. Liss, Inc., New York (1985)

EXAMINER:

Yunne Efron

DATE CONSIDERED:

1/15/00

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

BEST AVAILABLE COPY

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DOC NO.  
231/298

SERIAL NO.

~~To Be Assigned~~

APPLICANT:

Ben Margolis et al.

FILING DATE:

~~Hengrath~~

1/23/98

GROUP:

1642

4E	AS	Coussens et al., "Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with <i>neu</i> Oncogene", <u>Science</u> 230:1132-1139 (1985)
4E	AT	Creighton, <u>Proteins: Structures and Molecular Principles</u> , pp. 79-86, W.H. Freeman and Co., New York, (1983)
4E	AU	Davies, "Tracking neurotrophin function", <u>Nature</u> 368:193-194 (1994)
4E	AV	Dikic et al., "Shc Binding to Nerve Growth Factor Receptor is Mediated by the Phosphotyrosine Interaction Domain," <u>J. Biol. Chem.</u> 270:15125-15129 (1995)
4E	AW	Dougall et al., "The <i>neu</i> -oncogene: signal transduction pathways, transformation mechanisms and evolving therapies," <u>Oncogene</u> 9:2109-2123 (1994)
4E	AX	Fingl and Woodbury, Chapter 1, pp.1-46 in <u>The Pharmacological Basis of Therapeutics</u> (5th edition), eds. Goodman et al., MacMillan Publishing Co., Inc., New York (1975)
4E	AY	Fry et al., "New insights into protein-tyrosine kinase receptor signaling complexes," <u>Protein Science</u> 2:1785-1797 (1993)
4E	AZ	Hardie, D.G., "Roles of Protein Kinases and Phosphatases in Signal Transduction", <u>Symp. Soc. Exp. Bio.</u> 44:241-255 (1990)
4E	BA	Harris et al., "Breast Cancer (First of Three Parts)", <u>New England J. of Medicine</u> 327:319-328 (1992)
4E	BB	Hunter, T., "Cooperation between Oncogenes", <u>Cell</u> 64:249-270 (1991)
4E	BC	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda", <u>Science</u> 246:1275-1281 (1989)
4E	BD	Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in <i>Escherichia coli</i> ", <u>Proc. Natl. Acad. Sci. USA</u> 85:5879-5883 (1988)
4E	BE	Inouye and Inouye, "Up-promotor mutations in the <i>lpp</i> gene of <i>Escherichia coli</i> ", <u>Nucleic Acids Research</u> 13:3100-3111 (1985)
4E	BF	Kaplan et al., "The <i>trk</i> Proto-Oncogene Product: A Signal Transducing Receptor for Nerve Growth Factor", <u>Science</u> 252:554-558 (1991)
4E	BG	Kavanaugh and Williams, "An Alternative to SH2 Domains for Binding Tyrosine-Phosphorylated Proteins," <u>Science</u> 266:1862-1866 (1994)
4E	BH	Klein et al., "The <i>trkB</i> Tyrosine Protein Kinase is a Receptor for Brain-Derived Neurotrophic Factor and Neurotrophin-3", <u>Cell</u> 66:395-403 (1991)
4E	BI	Klein et al., "Disruption of the neurotrophin-3 receptor gene <i>trkC</i> eliminates Ia muscle afferents and results in abnormal movements", <u>Nature</u> 368:249-251 (1994)
4E	BJ	Koch et al., "SH2 and SH3 Domains: Elements That Control Interactions of Cytoplasmic Signaling Proteins", <u>Science</u> 252:668-674 (1991)
4E	BK	Köhler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity", <u>Nature</u> 256:495-497 (1975)
4E	BL	Lam et al., "A new type of synthetic peptide library for identifying ligand-binding activity", <u>Nature</u> 354:82-84 (1991)
4E	BM	Logan and Shenk, "Adenovirus tripartite leader sequence enhances translation of mRNAs late after infection", <u>Proc. Natl. Acad. Sci. USA</u> 81:3655-3659 (1984)
4E	BN	Lowy et al., "Isolation of Transforming DNA: Cloning the Hamster <i>aprt</i> Gene", <u>Cell</u> 22:817-823 (1980)

BEST AVAILABLE COPY

EXAMINER:

DATE CONSIDERED:

11/15/00

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:  
Ben Margolis et al.FILING DATE:  
Herewith 1/23/98GROUP:  
1642

	BO	Marasco et al., "Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gp120 single-chain antibody", <u>Proc. Natl. Acad. Sci. USA</u> 90:7889-7893 (1993)
	BP	Marshall, "Search for a Killer: Focus Shifts from Fat to Hormones", <u>Science</u> 259:618-621 (1993)
	BQ	Martin-Zanca et al., "A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences", <u>Nature</u> 319:743-748 (1986)
	BR	Mayer et al., "A novel viral oncogene with structural similarity to phospholipase C", <u>Nature</u> 332:272-275 (1988)
	BS	Miller, "Human gene therapy comes of age", <u>Nature</u> 357:455-460 (1992)
	BT	Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains", <u>Proc. Natl. Acad. Sci. USA</u> 81:6851-6855 (1984)
	BU	Mulligan and Berg, "Selection for animal cells that express the <i>Escherichia coli</i> gene coding for xanthine-guanine phosphoribosyltransferase", <u>PNAS</u> 78:2072-2076 (1981)
	BV	Musacchio et al., "The PH domain: a common piece in the structural patchwork of signalling proteins", <u>TIBS</u> 18:343-348 (1993)
	BW	Neuberger et al., "Recombinant antibodies possessing novel effector functions", <u>Nature</u> 312:604-608 (1984)
	BX	O'Hare et al., "Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase", <u>PNAS</u> 78:1527-1531 (1981)
	BY	Obermeier et al., "Tyrosine 785 is a major determinant of Trk-substrate interaction", <u>The EMBO Journal</u> 12:933-941 (1993)
	BZ	Obermeier et al., "Identification of Trk Binding Sites for SHC and Phosphatidylinositol 3'-Kinase and Formation of a Multimeric Signaling Complex", <u>J. Bio. Chem.</u> 268:22963-22966 (1993)
	CA	Padhy et al., "Identification of a Phosphoprotein Specifically Induced by the Transforming DNA of Rat Neuroblastomas", <u>Cell</u> 28:865-871 (1982)
	CB	Park et al., "Mechanism of <i>met</i> Oncogene Activation", <u>Cell</u> 45:895-904 (1986)
	CC	Pawson and Gish, "SH2 and SH3 Domains: From Structure to Function", <u>Cell</u> 71:359-362 (1992)
	CD	Pawson and Schlessinger, "SH2 and SH3 domains", <u>Current Biology</u> 3(7):434-442 (1993)
	CE	Pellicci et al., "A Novel Transforming Protein (SHC) with an SH2 Domain Is Implicated in Mitogenic Signal Transduction", <u>Cell</u> 70:93-104 (1992)
	CF	Pendergast et al., "BCR-ABL-Induced Oncogenesis is Mediated by Direct Interaction with the SH2 Domain of the GRB-2 Adaptor Protein", <u>Cell</u> , 75:175-185 (1993)
	CG	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 <sup>erbB4</sup> ", <u>Nature</u> 366:473-475 (1993)
	CH	Posada and Cooper, "Molecular Signal Integration. Interplay Between Serine, Threonine and Tyrosine Phosphorylation", <u>Mol. Biol. of the Cell</u> 3:583-592 (1992)
	CI	Pulciani et al., "Oncogenes in solid human tumours", <u>Nature</u> 300:539-542 (1982)
	CJ	Sadowski et al., "A Nucleocapsid Domain Conserved among Cytoplasmic Protein-Tyrosine Kinases Modifies the Kinase Function and Transforming Activity of Fujinami Sarcoma Virus P130 <sup>src</sup> ", <u>Mol. and Cell. Biol.</u> 6:4396-4408 (1986)
	CK	Samanta et al., "Ligand and p185 <sup>neu</sup> density govern receptor interactions and tyrosine kinase activation", <u>Proc. Natl. Acad. Sci. USA</u> 91:1711-1715 (1994)

BEST AVAILABLE COPY

EXAMINER:

DATE CONSIDERED:

1/15/00

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S  
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:  
Ben Margolis et al.FILING DATE:  
Herewith 1/23/98GROUP:  
1642

44	CL	Santerre et al., "Expression of prokaryotic genes for hygromycin B and G418 resistance as dominant-selection markers in mouse L cells", <u>Gene</u> 30:147-156 (1984)
44	CM	Schechter et al., "The <i>neu</i> oncogene: an <i>erb-B</i> -related gene encoding a 185,000-M, tumour antigen", <u>Nature</u> 312:513-516 (1984)
44	CN	Schlessinger and Ullrich, "Growth Factor Signaling by Receptor Tyrosine Kinases", <u>Neuron</u> 9:383-391 (1992)
44	CO	Schlessinger, "Signal transduction by allosteric receptor oligomerization", <u>Trends Biochem. Sci.</u> 13:443-447 (1988)
44	CP	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the <i>HER-2/neu</i> Oncogene", <u>Science</u> 235:177-185 (1987)
44	CQ	Slamon et al., "Studies of the <i>HER-2/neu</i> Proto-oncogene in Human Breast and Ovarian Cancer", <u>Science</u> 244:707-712 (1989)
44	CR	Sliwkowski et al., "Coexpression of <i>erbB2</i> and <i>erbB3</i> Proteins Reconstitutes a High Affinity Receptor for Heregulin", <u>J. Biol. Chem.</u> 269:14661-14665 (1994)
44	CS	Smeyne et al., "Severe sensory and sympathetic neuropathies in mice carrying a disrupted <i>Trk/NGF</i> receptor gene", <u>Nature</u> 368:246-248 (1994)
44	CT	Songyang et al., "SH2 Domains Recognize Specific Phosphopeptide Sequences", <u>Cell</u> 72:767-778 (1993)
44	CU	Szybalska and Szybalski, "Genetics of Human Cell Lines, IV. DNA-Mediated Heritable Transformation of a Biochemical Trait", <u>PNAS</u> 48:2026-2034 (1962)
44	CV	Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", <u>Nature</u> 314:452-454 (1985)
44	CW	Ullrich and Schlessinger, "Signal Transduction by Receptors with Tyrosine Kinase Activity", <u>Cell</u> 61:203-212 (1990)
44	CX	Van Heeke and Schuster, "Expression of Human Asparagine Synthetase in <i>Escherichia coli</i> ", <u>J. Biol. Chem.</u> 264:5503-5509 (1989)
44	CY	Wada et al., "Intermolecular Association of the p185 <sup>neu</sup> Protein and EGF Receptor Modulates EGF Receptor Function", <u>Cell</u> 61:1339-1347 (1990)
44	CZ	Ward et al., "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ", <u>Nature</u> 341:544-546 (1989)
44	DA	Wigler et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", <u>Cell</u> 11:223-232 (1977)
44	DB	Wigler et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene", <u>PNAS</u> 77:3567-3570 (1980)
44	DC	Yajnik et al., "Identification of Residues within the SHC Phosphotyrosine Binding/Phosphotyrosine Interaction Domain Crucial for Phosphopeptide Interaction", <u>J. Biol. Chem.</u> 271:1813-1816 (1996)
44	DD	Yamamoto et al., "Similarity of protein encoded by the human <i>C-erb-B-2</i> gene to epidermal growth factor receptor", <u>Nature</u> 319:230-234 (1986)

BEST AVAILABLE COPY

EXAMINER:

Yvonne Eber

DATE CONSIDERED:

1/15/00

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.